Analysis of possible drug resistance mechanisms and countermeasures for venetoclax/venetoclax (Vekela)

Venetoclax (also known as venetoclax) is a highly selective BCL-2 inhibitor originally approved for the treatment of blood cancers such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The drug works by inducing apoptosis in tumor cells and has achieved remarkable results in the field of targeted therapy. However, with the prolongation of clinical application, some patients developed drug resistance after using venetoclax, leading to disease progression or recurrence. The following will conduct a systematic analysis from three aspects: drug resistance mechanisms, influencing factors and clinical response strategies.

The mechanism of action and basis of drug resistance of venetoclax

Veneclase directly inhibits B cell lymphoma-2(BCL-2) protein, releasing its inhibition on pro-apoptotic proteins (such as BAX, BAK), thereby initiating the apoptosis pathway. In a variety of BCL-2-dependent tumors (especially CLL and AML), venetoclax can significantly reduce tumor cell survival. However, cancer cells are often highly adaptable and can evade drug inhibition by changing the apoptosis signaling network. For example, during long-term medication, tumor cells may up-regulate anti-apoptotic proteins such as BCL-XL and MCL-1, and some patients may also develop BCL-2 gene mutations, thereby weakening the binding effect of venetoclax to the target. This biological adaptation paves the way for the emergence of drug resistance.

Main resistance mechanisms of venetoclax

Veneclase resistance can be divided into two categories: "primary resistance" and "secondary resistance". Primary drug resistance is usually related to the intrinsic characteristics of the tumor, such as high expression of MCL-1 or BCL-XL, which results in poor drug efficacy. Secondary drug resistance mostly occurs after long-term treatment, mainly including the following mechanisms:

1. Target mutation mechanism: Some patients develop BCL-2 gene mutations (such as G101V mutations). This mutation will significantly reduce the binding affinity between venetoclax and BCL-2, making the drug ineffective.

2.Anti-apoptotic protein replacement: tumor cells upregulateMCL-1, BCL-XL and other proteins to "replace" the anti-apoptotic function of BCL-2, thereby bypassing the action pathway of venetoclax.

3.Metabolism and signaling pathway changes: Studies have found that the activation of PI3K/AKT, MAPK and other signaling pathways can enhance the survival ability of tumor cells and reduce dependence on BCL-2 inhibitors, thereby forming drug resistance.

4.Cell environment factors: Cytokines in the tumor microenvironment (such as IL-6, CXCL12) can activate protective signals, allowing leukemia cells to escape drug-induced apoptosis in the bone marrow microenvironment.

Resistance detection and risk assessment

In the clinic, early identification of drug resistance is crucial for treatment decisions. Common detection methods include:

1.Gene sequencing: Using NGS technology to monitor BCL-2 mutations (such as G101V, D103Y, etc.), the risk of drug resistance can be discovered in advance.

2.Protein expression analysis: Use flow cytometry or Western blotting to detect the expression levels of MCL-1 and BCL-XL to evaluate the tendency of drug resistance.

3.Microenvironmental marker assessment: detect CXCL12/CXCR4 axis activity, cytokine levels, etc., to predict the possibility of drug resistance development.

These tests can help doctors determine whether a patient is still appropriate to continue taking venetoclax or if treatment should be adjusted.

Clinical response and treatment strategies

In response to venetoclax resistance, current research and clinical exploration have proposed a variety of response options.

First of all, combination treatment strategies can be used, such as venetoclax combined with azacitidine (Azacitidine) or hypomethylating drugs (HMA) in AMLcan overcome some drug resistance; in CLL, combination with BTK inhibitors (such as ibrutinibIbrutinib, zanubrutinibZanubrutinib) can enhance the synergistic effect of the apoptosis signaling pathway.

Secondly, for drug resistance caused by upregulation of MCL-1 or BCL-XL, combined use may be consideredMCL-1 inhibitors (such as S64315) or BCL-XL inhibitors for targeted combination.

Again, for patients with BCL-2 mutations, a new generation of BCL-2 inhibitors (such as Lisaftoclax, Navitoclax) can be explored as an alternative to venetoclax.

In addition, the emergence of drug resistance can be delayed by optimizing treatment duration and dosage, intermittent medication strategies, and maintaining and monitoring molecular residual disease (MRD) levels.

In summary, the resistance problem of venetoclax is an important challenge in clinical application, and its mechanism is complex and multi-dimensional. Through accurate detection, reasonable combination and dynamic adjustment of treatment strategies, the progression of drug resistance can be effectively delayed or reversed. In the future, with the development of new BCL-2 family inhibitors and immune combination therapies, venetoclax's drug resistance response plan will be more individualized and precise, thereby further improving the long-term survival benefits of patients with hematological tumors.

Reference materials:https://www.drugs.com/